Purchase of AstraZeneca PLC Ordinary Shares of US$0.25 of 60,000 shares at £121.02
AstraZeneca PLC
18 September 2026
18 September 2026
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announces that it was notified on 16 September 2026 that Pascal Soriot, Chief Executive Officer of the Company, purchased 60,000 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 14 September 2026, as set out below.
|
PDMR |
Position |
Nature of the transaction |
Date |
Quantity |
Price |
|
Pascal Soriot |
Executive Director and Chief Executive Officer |
Purchase of Ordinary Shares |
14/09/2026 |
60,000 |
GB£121.02 |
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Pascal Soriot |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Executive Director and Chief Executive Officer |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
AstraZeneca PLC |
||||
|
b)
|
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 |
||||
|
b)
|
Nature of the transaction |
Purchase of AstraZeneca PLC Ordinary Shares of US$0.25 |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
Not applicable - single transaction |
||||
|
e) |
Date of the transaction |
14 September 2026 |
||||
|
f) |
Place of the transaction |
LON |
||||
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.